Skip to Main Content

Paper Details

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Rheumatology (Oxford)
38
2021
Author NameAffiliation
Murray B UrowitzToronto Western Hospital
  • 1 - 1

Datasets

Release 1.2